Skip to main content

Results of Annual General Meeting

The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Thursday, May 27, 2021. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll.

The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.

Resolutions

   

For

   

%

   

Against

   

%

   

Withheld

   

Total votes cast

001. To approve the Company’s Annual Report and Accounts for year ended 31 December 2020

   

225,240,798

   

100.00%

   

10,921

   

0.00%

   

273,846

   

225,251,719

002. To approve the Directors’ Remuneration Report

   

200,319,991

   

89.74%

   

22,895,826

   

10.26%

   

2,309,748

   

223,215,817

003. To approve the Directors’ Remuneration Policy

   

187,285,809

   

83.90%

   

35,930,008

   

16.10%

   

2,309,748

   

223,215,817

004. To elect Dr. Raju Kucherlapati as a director

   

222,659,203

   

98.73%

   

2,865,525

   

1.27%

   

837

   

225,524,728

005. To elect Dr. John LaMattina as a director

   

218,438,727

   

96.86%

   

7,086,001

   

3.14%

   

837

   

225,524,728

006. To elect Ms. Kiran Mazumdar-Shaw as a director

   

189,257,653

   

84.32%

   

35,193,037

   

15.68%

   

1,074,875

   

224,450,690

007. To elect Dame Marjorie Scardino as a director

   

222,228,072

   

98.54%

   

3,296,656

   

1.46%

   

837

   

225,524,728

008. To elect Mr. Christopher Viehbacher as a director

   

199,985,210

   

88.68%

   

25,539,518

   

11.32%

   

837

   

225,524,728

009. To elect Dr. Robert Langer as a director

   

218,164,180

   

96.74%

   

7,360,548

   

3.26%

   

837

   

225,524,728

010. To elect Ms. Daphne Zohar as a director

   

225,474,510

   

99.98%

   

50,218

   

0.02%

   

837

   

225,524,728

011. To elect Dr. Bharatt Chowrira as a director

   

225,473,830

   

99.98%

   

50,898

   

0.02%

   

837

   

225,524,728

012. To reappoint KPMG LLP as Auditors of the Company

   

225,291,096

   

99.90%

   

234,469

   

0.10%

   

0

   

225,525,565

013. To authorize the Audit Committee to determine the Auditors' remuneration

   

225,483,695

   

99.98%

   

41,870

   

0.02%

   

0

   

225,525,565

014. To authorize the allotment of shares

   

221,538,872

   

98.23%

   

3,986,693

   

1.77%

   

0

   

225,525,565

015. To disapply pre-emption rights

   

225,102,915

   

99.81%

   

422,650

   

0.19%

   

0

   

225,525,565

016. To further disapply pre-emption rights for acquisitions and specified capital investments.

   

215,316,258

   

95.47%

   

10,209,307

   

4.53%

   

0

   

225,525,565

017. To authorize market purchase of own shares

   

225,235,005

   

99.89%

   

258,692

   

0.11%

   

31,868

   

225,493,697

018. To authorize general meetings to be called on not less than 14 clear days’ notice

   

222,063,258

   

98.46%

   

3,462,307

   

1.54%

   

0

   

225,525,565

Notes:

 

(1)

A vote “Withheld” is not a vote in law and is not counted in the calculation of the votes “For” or “Against” a resolution.

 

(2)

As at May 27, 2021 the number of issued shares in the Company was 286,018,538 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company’s Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

 

(3)

The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company’s website https://investors.puretechhealth.com/financials-filings/reports and on the National Storage Mechanism.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech’s Founded Entities, is comprised of 26 therapeutics and therapeutic candidates, including two that have received FDA clearance and European marketing authorization, as of the date of PureTech’s most recently filed Annual Report on Form 20-F. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company’s unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.